Post-Infectious Dysautonomia: Insights into Clinical Phenotypes and Disease Pathogenesis
Project Number1K23AI180356-01A1
Former Number1K23AI180356-01
Contact PI/Project LeaderADLER, BRITTANY LEE
Awardee OrganizationJOHNS HOPKINS UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
Dysautonomia, or autonomic nervous system dysfunction, is a common and disabling post-infectious syndrome
that can occur following COVID-19 and Lyme disease. Dysautonomia accounts for many of the symptoms in
Post-Acute Sequelae of COVID-19 (PASC, also called Long COVID) and Post-Treatment Lyme Disease (PTLD,
also called Chronic Lyme). Dysautonomia has a wide variety of manifestations, including POTS (Postural
orthostatic tachycardia syndrome), gastrointestinal dysmotility, interstitial cystitis, and neuropathic pain. A small-
fiber neuropathy is also often present. The mechanisms of dysautonomia in patients with PASC and PTLD are
not well understood. A subset of patients with dysautonomia have ganglionic acetylcholine receptor (gAchR)
autoantibodies and often respond to immunomodulatory therapy with intravenous immunoglobulin (IVIG),
implicating autoimmune destruction of small nerve fibers as a potential mechanism of dysautonomia. Some
patients without gAchR antibodies still respond to IVIG, suggesting that some autoantibodies remain to be
discovered. This project will leverage the clinical resources of the Johns Hopkins post-Acute COVID Clinic, the
Lyme Disease Research Center, and the POTS Clinic to identify patients with post-infectious dysautonomia.
Patients with confirmed PASC and PTLD dysautonomia will prospectively undergo objective autonomic testing
in the Autonomic Lab, histopathological examination of small-fiber nerve density on skin biopsy, and clinical
phenotyping using patient-reported outcome measures. In Aim 1, we will identify distinct clinical subgroups using
unbiased latent variable cluster analysis. In Aim 2, we will determine the clinical significance of small-fiber
neuropathy in post-infectious dysautonomia by investigating the association with disease severity, and will
correlate clinical outcomes with changes in nerve fiber density over time. In Aim 3, we will perform
immunoprecipitation and mass spectrometry to identify novel autoantibodies targeting the sympathetic ganglia
in post-infectious dysautonomia. This Award will help the candidate, who is currently an Assistant Professor at
Johns Hopkins University, develop her career as an independent physician-scientist with a focus on
dysautonomia. Throughout the Award period, she will enhance her clinical research and biostatistical skills
through hands-on experience and formal coursework. A key focus of the proposal is for Dr. Adler to refine her
skills in autonomic testing and learn how to perform transcranial doppler ultrasound which is currently being
integrated into the Autonomic Lab and will be a key skill that she will utilize throughout her research career. She
has assembled an exceptional mentorship team that each provides complementary skills to ensure the success
of this project, and includes experts in autonomic neuroscience and peripheral neuropathies, PASC and PTLD,
immunology and autoantibody discovery, and biostatistics. With the guidance of her mentorship team, the
candidate will develop an independent translational research program and a track-record that will lead to a
successful R01 application.
Public Health Relevance Statement
PROJECT NARRATIVE
A subset of patients develop chronic disabling symptoms of autonomic dysfunction such as fatigue and
dizziness following infection with COVID-19 (Long Covid) or Lyme disease (Chronic Lyme), but the
mechanisms through which this occurs are not understood. We will study a group of patients with chronic
post-infectious autonomic symptoms to understand the markers and subtypes of this syndrome, and to test
whether it is driven by an autoimmune attack on the nerves leading to chronic nerve damage.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
001910777
UEI
FTMTDMBR29C7
Project Start Date
01-January-2025
Project End Date
31-December-2029
Budget Start Date
01-January-2025
Budget End Date
31-December-2025
Project Funding Information for 2025
Total Funding
$198,720
Direct Costs
$184,000
Indirect Costs
$14,720
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$198,720
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1K23AI180356-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1K23AI180356-01A1
Patents
No Patents information available for 1K23AI180356-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1K23AI180356-01A1
Clinical Studies
No Clinical Studies information available for 1K23AI180356-01A1
News and More
Related News Releases
No news release information available for 1K23AI180356-01A1
History
No Historical information available for 1K23AI180356-01A1
Similar Projects
No Similar Projects information available for 1K23AI180356-01A1